20/20 Biolabs earnings were -$7.7M for the trailing 12 months ending Sep 30, 2026, with N/A growth year over year. The latest AIDX earnings report on Sep 30, 2026 announced Q3 2026 earnings of -$1.5M, down 45.4% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AIDX reported annual earnings of -$3.7M, with -32.7% growth.
On AIDX's earnings call on Nov 16, 2026, 20/20 Biolabs (NASDAQ: AIDX) reported Q3 2026 earnings per share (EPS) of -$0.12, up 29.41% year over year. Total AIDX earnings for the quarter were -$1.50 million. In the same quarter last year, 20/20 Biolabs's earnings per share (EPS) was -$0.17.
As of the last 20/20 Biolabs earnings report, 20/20 Biolabs is currently losing money. 20/20 Biolabs's net profit (also called net income) for the twelve months ending Sep 30, 2026 was -$6.36 million, a 72.93% increase year over year.
What was AIDX's earnings growth in the past year?
As of 20/20 Biolabs's earnings date in Nov 16, 2026, 20/20 Biolabs's earnings has grown year over year. AIDX earnings in the past year totalled -$7.68 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.